Satellite Cells Derived from Obese Humans with Type 2 Diabetes and Differentiated into Myocytes In Vitro Exhibit Abnormal Response to IL-6 by Scheele, Camilla et al.
Satellite Cells Derived from Obese Humans with Type 2
Diabetes and Differentiated into Myocytes In Vitro
Exhibit Abnormal Response to IL-6
Camilla Scheele*, Søren Nielsen, Meghan Kelly, Christa Broholm, Anders Rinnov Nielsen, Sarah Taudorf,
Maria Pedersen, Christian P. Fischer, Bente Klarlund Pedersen
The Centre of Inflammation and Metabolism at Department of Infectious Diseases and Copenhagen Muscle Research Centre, Rigshospitalet, The Faculty of Health
Sciences, University of Copenhagen, Copenhagen, Denmark
Abstract
Obesity and type 2 diabetes are associated with chronically elevated systemic levels of IL-6, a pro-inflammatory cytokine
with a role in skeletal muscle metabolism that signals through the IL-6 receptor (IL-6Ra). We hypothesized that skeletal
muscle in obesity-associated type 2 diabetes develops a resistance to IL-6. By utilizing western blot analysis, we
demonstrate that IL-6Ra protein was down regulated in skeletal muscle biopsies from obese persons with and without type
2 diabetes. To further investigate the status of IL-6 signaling in skeletal muscle in obesity-associated type 2 diabetes, we
isolated satellite cells from skeletal muscle of people that were healthy (He), obese (Ob) or were obese and had type 2
diabetes (DM), and differentiated them in vitro into myocytes. Down-regulation of IL-6Ra was conserved in Ob myocytes. In
addition, acute IL-6 administration for 30, 60 and 120 minutes, resulted in a down-regulation of IL-6Ra protein in Ob
myocytes compared to both He myocytes (P,0.05) and DM myocytes (P,0.05). Interestingly, there was a strong time-
dependent regulation of IL-6Ra protein in response to IL-6 (P,0.001) in He myocytes, not present in the other groups.
Assessing downstream signaling, DM, but not Ob myocytes demonstrated a trend towards an increased protein
phosphorylation of STAT3 in DM myocytes (P=0.067) accompanied by a reduced SOCS3 protein induction (P,0.05), in
response to IL-6 administration. Despite this loss of negative control, IL-6 failed to increase AMPKa2 activity and IL-6 mRNA
expression in DM myocytes. There was no difference in fusion capacity of myocytes between cell groups. Our data suggest
that negative control of IL-6 signaling is increased in myocytes in obesity, whereas a dysfunctional IL-6 signaling is
established further downstream of IL-6Ra in DM myocytes, possibly representing a novel mechanism by which skeletal
muscle function is compromised in type 2 diabetes.
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Introduction
Type 2 diabetes is a condition of metabolic failure preceded by
skeletal muscle insulin resistance. It is possible that concurrent
resistance to additional growth factors or cytokines is established
and contributes to the muscular phenotype of type 2 diabetes. One
candidate protein involved in skeletal muscle metabolism, and also
regulated during obesity and diabetes is interleukin (IL)-6. The
role of IL-6 in skeletal muscle metabolism has been debated. IL-6
is markedly produced by contracting skeletal muscle and released
into plasma during the post-exercise period [1,2] when insulin
sensitivity is enhanced [3]. In sharp contrast, adipose production
and secretion of IL-6 [4] is chronically elevated in obese people
[5,6] and elevated plasma IL-6 is an independent risk factor for
developing type 2 diabetes [6,7]. Thus, it has been suggested that
IL-6 contributes to obesity-associated insulin resistance [8],
supported by the findings that increased plasma levels of IL-6
are associated with both obesity and insulin resistance [7,9,10].
However, it was recently shown that IL-6 stimulates insulin
production by inducing Glucagon-like peptide-1 (GLP-1) expres-
sion [11]. This important finding suggests that the increased IL-6
production associated with obesity and insulin resistance may in
fact represent a mechanism for increasing the production of
insulin, an idea that warrant further investigation.
At the cell membrane, IL-6 binds to an IL-6Ra-gp130 receptor
complex, activating JAK/STAT3 signaling. IL-6 also induces
Suppressor of cytokine signaling 3 (SOCS-3) gene expression via
JAK/STAT3 signaling, acting in a negative feedback loop. SOCS-
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of JAK substrates, such as the STAT proteins involved in cytokine
signaling [12]. In addition, SOCS-3 has been described as an
inhibitor of the phosphorylation of IRS-1 [13]. In line with this,
increased SOCS-3 impairs glycogen synthesis and glucose trans-
port [14,15]. Thus, a dysregulation of the IL-6 signaling pathway
involving a dysregulation of SOCS-3 could possibly be related to
a deficient insulin signaling.
Skeletal muscle expresses IL-6Ra, which also increases with
physical activity [16] suggesting an autocrine IL-6 signaling loop
(2). In support of this idea, it was shown that IL-6 mRNA
expression was induced in human skeletal muscle in response to
IL-6 infusion [17], while in vitro administration of recombinant IL-
6 induced IL-6 mRNA expression in the murine muscle cell line,
C2C12 [18]. IL-6 has been shown to stimulate metabolic rate in
skeletal muscle cells by increasing AMPKa2 activity [19,20], fatty
acid oxidation and glucose uptake [21–23].In order to model
human muscle signaling in vitro, several studies have previously
demonstrated that the so called satellite cells, which are muscle
stem cells stored at the sarcolemma, can be isolated from muscle
biopsies and differentiated into myotubes in vitro. Interestingly, it
has also been shown that muscle precursor cells isolated from
skeletal muscle biopsies from individuals with type 2 diabetes, have
established donor-specific phenotypes, which transpires following
differentiation into myocytes in vitro. So far, it has been
demonstrated that myocytes derived from people with type 2
diabetes have reduced insulin sensitivity and reduced glucose
transport [24–27], reduced lipid oxidation [28] and an increased
activity of inflammatory markers [27].
Interestingly, IL-6 has been shown essential for muscle
hypertrophy to occur through activation of STAT3 signaling in
murine satellite cells [29]. In contrast, other studies report a muscle
atrophic effect of long-term exposure of IL-6 [30,31]. Thus,
chronic exposure of elevated levels of IL-6 might result in
a dysregulation of IL-6 signaling in skeletal muscle cells.
Our aim with this study was to investigate whether IL-6
signaling is affected in skeletal muscle or in satellite cells of people
with type 2 diabetes. We hypothesized that satellite cells derived
from people with type 2 diabetes would demonstrate a deficient
response to IL-6, which could contribute to the metabolic
dysfunction of skeletal muscle in type 2 diabetes. We measured
the abundance of the IL-6 receptor (IL-6Ra) in skeletal muscle
biopsies and isolated satellite cells from healthy (He), obese (Ob) or
obese persons with type 2 diabetes (DM). These cells were
differentiated in vitro and utilized as a model to study IL-6 signaling
in human skeletal muscle. We achieved our aim and identified
a down-regulation of IL-6Ra in obesity and an abnormal IL-6
signaling in myocytes from people with type 2 diabetes.
Results
Dysregulation of IL-6Ra in Myocytes of People with
Obesity
To investigate whether a deficient IL-6 signaling was established
in skeletal muscle of subjects with obesity or type 2 diabetes, we
measured the protein abundance of IL-6Ra in skeletal muscle
biopsies from normal glucose tolerant (NGT) subjects and people
with type 2 diabetes that were either non-obese or obese (DM)
(Table 1). Western blot and a two-way Anova demonstrated an
effect of obesity (P,0.05) but no independent effect of diabetes
(Figure 1A and Figure S1). We then investigated the IL-6Ra
protein abundance in an in vitro model consisting of satellite cells
isolated from healthy (He), obese (Ob) and people with type 2
diabetes (DM) (Table 2) and differentiated in vitro into myocytes.
Interestingly, the down-regulation of IL-6Ra protein observed in
tissue was conserved in Ob myocytes (despite being isolated from
a different cohort) (P,0.05), but not in DM myocytes (Figure 1B
and C). Furthermore, when stimulating the myocytes with
recombinant IL-6 for 30, 60 and 120 minutes, IL-6 was strongly
regulated over time in He myocytes with a trend towards an initial
up-regulation at 30 minutes of IL-6 incubation, followed by
a gradual, highly time-dependent down-regulation (P,0.001)
(Figure 1D). In contrast, in Ob myocytes, the IL-6Ra protein
expression in response to IL-6 was down-regulated already at
30 min of IL-6 incubation (P,0.01), compared to He myocytes,
and were not further down-regulated over time. Finally, DM
myocytes were not down-regulated at all but had an up-regulated
IL-6Ra response to IL-6 when compared as a group to Ob
myocytes (P,0.05). This data is intriguing as the diabetic cell
donor subjects were also obese and in muscle tissue IL-6Ra
protein was down-regulated in both obese normal glucose tolerant
individuals and in obese individuals with type 2 diabetes. To
investigate the potential consequence of the altered response
observed in Ob and DM myocytes, we assessed downstream
signaling.
Dysregulation of IL-6 Induced STAT3/SOCS3 in Myocytes
of People with type 2 Diabetes
To investigate whether downstream IL-6 signaling was affected
in the myocytes, we stimulated He, Ob and DM myocytes with
recombinant IL-6 or PBS for 30, 60 and 120 minutes and
measured downstream activation of STAT3 protein signaling,
presented as phosphorylated STAT3/total STAT3 (Figure 2A and
2B). Interestingly, while we observed no difference between He
and Ob myocytes, there was a clear trend towards an increased
activation of STAT3 in DM myocytes compared to He myocytes
(P=0.067) and compared to Ob myocytes (P=0.056) (Figure 2B).
A possible mechanism for this observation could be a loss of
control by the suppressor of cytokine signaling 3 (SOCS3). Thus,
we measured protein levels of SOCS3 in the same samples as for
pSTAT3/STAT3. Viewing the baseline control samples (stimu-
lated with PBS only), there was a trend towards an increased
SOCS3 expression in both Ob and DM myocytes, however
without reaching significance (P=0.138 for Ob myocytes and
P=0.238 for DM myocytes) (Figure 2C). However, when
comparing the fold change of PBS and IL-6 treated samples
between the groups, we observed a reduced SOCS3 protein up-
regulation in response to IL-6 in DM myocytes compared to He
myocytes (P,0.05) (Figure 2D). Interestingly, in response to IL-6,
Ob myocytes seemed to activate STAT3 and SOCS3 to a similar
level as did He myocytes, indicating that the dysregulation of IL-6
signaling at this level only occurred in DM myocytes (Figure 2B
and 2D). Hence, these data indicate that DM myocytes, but not
Ob myocytes, have increased pSTAT3 response accompanied by
a reduced SOCS3 feedback control mechanism.
Resistance to IL-6 Induced IL-6 mRNA Expression in DM
Myocytes
As mentioned in the introduction, IL-6 has been described to
induce the expression of IL-6 in skeletal muscle cells [17,18]. To
investigate possible differences in IL-6 enhancement signaling
between He and DM myocytes, we incubated human myocytes
(Table 3) with recombinant IL-6 for 1 hour. This treatment
induced IL-6 mRNA expression in He myocytes while DM
myocytes did not respond (Figure 3A). We then targeted the
endogenous IL-6 signaling by knocking down the expression of IL-
6Ra, by transfecting the myocytes with siRNAs targeting IL-6Ra
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of IL-6 and should therefore result in a reduced IL-6 expression.
Indeed, 48 hours of knockdown of IL-6Ra resulted in a down-
regulation of IL-6 in He myocytes but not in DM myocytes
(Figure 3C). Notably, IL-6Ra was more reduced in the He
myocytes (,80%, P,0.01) than in the DM myocytes (,60%,
P,0.05), possibly partly explaining the lack of response in IL-6
expression. However, there was no difference between dCT-values
between knockdown samples for the two groups (Figure S2) and
IL-6 mRNA expression correlated with % knockdown of IL-6Ra
in He myocytes (R
2=0.92, P,0.05) but not in DM myocytes
(R
2=0.156, P,0.56) (Figure S2), indicating that the lack of
changes in IL-6 expression following IL-6R knockdown in DM
myocytes is likely to reflect a deficient regulation of IL-6 signaling.
Due to a limitation of material, these experiments were performed
on a different set of cells than the ones presented above and the
obese group was not included. This data indicate that even though
STAT3 phosphorylation in response to IL-6 is increased, endpoint
gene expression activation fails in DM myocytes, possibly
suggesting that the reduced SOCS3 activation and increased
STAT3 activation is part of a compensatory mechanism for
a reduced IL-6 signaling, i.e. an IL-6 resistance.
Resistance to IL-6 Induced AMPKa2 Activity in DM
Myocytes
It has previously been shown that IL-6 specifically increase
AMPKa2 activity [19,20]. Therefore, to further evaluate the
potential consequences of IL-6 resistance in type 2 diabetes, we
assessed AMPK activity in response to 30 and 60 minutes of
exposure to recombinant IL-6 in He myocytes and DM myocytes
(Table 2). While no effect was observed on AMPKa1 activity in
either of the cell groups (Figure 4A), we found a substantial
Figure 1. IL-6Ra protein expression in skeletal muscle tissue biopsies and in He, Ob and DM myocytes in response to IL-6. (A) Protein
expression of IL-6Ra was assessed in skeletal muscle biopsies from the vastus lateralis muscle of non-obese (n=10) or obese (n=10) normal glucose
tolerant (NGT) subjects and non-obese (n=10) or obese (n=9) subjects with type 2 diabetes (Table 1), using western blot analysis. Due to the
variability in these in vivo samples, all blots are presented in Figure S1. A two-way ANOVA was performed, comparing the effect of obesity and the
effect of diabetes on IL-6Ra protein expression. (B) Protein expression of IL-6Ra was assessed in satellite cells isolated from healthy (He) (n=7), obese
(Ob) (n=7) and obese people (n=7) with type 2 diabetes (DM) (Table 2). Satellite cells were differentiated into myocytes and treated with IL-6
(100 ng/ml) or control (PBS) for 30, 60 and 120 min. (C) Baseline IL-6Ra protein expression was normalized to total protein expression (as determined
by reactive brown staining) and compared between groups by two-way ANOVAs. (D) IL-6 induced IL-6Ra protein expression was normalized to total
protein and compared between groups by two-way ANOVAs and effect of time within groups was assessed with one-way ANOVAs. Data are
presented as fold change (FC) between the control samples presented in B and C and samples treated with IL-6 (100 ng/ml). Data are mean 6 SE.
Groups were compared in pairs (i.e. He vs Ob, He vs DM and Ob vs DM) by two-way ANOVAs. Results from ANOVAs are marked in the figures with
connecting capped arcs. *Results from Bonferroni post-tests, relative to He myocytes; *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0039657.g001
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in DM myocytes (Figure 4B). These data further emphasize an
occurrence of an IL-6 resistance in DM myotubes, which may
have consequences for the regulation of muscle metabolism.
No Difference in Fusion Capacity between Myocytes from
Healthy, Obese and People with Type 2 Diabetes
IL-6 has been shown to promote myogenesis [29] and SOCS3
promotes myogenic differentiation by down regulating the STAT3
signaling pathway [32]. Thus, we evaluated the myogenic status of
muscle precursor cells isolated from healthy (He), obese (Ob) or
people with type 2 diabetes (DM) (Table 1) differentiated into
myotubes in vitro. Cells were stained for Myosin-2, widely utilized
as a marker for mature myocytes and DAPI (Figure S3) and fusion
index was determined by dividing the amount of DAPI positive
cells within Myosin-2 positive myotubes with the total amount of
DAPI positive cells. The same size of photograph was obtained
from each slide and all DAPI positive cells in the photograph were
counted. The average counted cells/photograph was 4486124 for
He myocytes; 4156102 for Ob myocytes and 4716150 for DM
myocytes (Figure S3). While phase contrast microscopy indicated
that the majority of cells were fused into myotubes (data not
shown), the average fusion index was determined to be 25%,
suggesting that cell populations included both immature and
mature myotubes. There was no significant difference in fusion
index between the groups, possibly indicating that a ‘‘diabetic
environment’’ or stimulating chronically with IL-6 might be
necessary for the potential differences in differentiation capacity
between the groups to transpire.
Discussion
We have identified an abnormal IL-6 signaling in differentiated
muscle precursor cells isolated from people with obesity and type 2
diabetes. We observed a reduced protein expression of IL-6Ra in
skeletal muscle of people with obesity and with and without type 2
diabetes. This down-regulation of IL-6Ra protein was also found
in Ob but not DM myocytes. However, further downstream, an
abnormal STAT3/SOCS3 protein signaling response was estab-
lished in DM but not Ob myocytes. Despite an increased pSTAT3
response, DM myocytes appeared resistant to IL-6 induced IL-6
gene expression and AMPKa2 activation. Confocal imaging and
immunostaining for myosin 2 suggested equal differentiation status
in all three cell groups.
The differences we observe in IL-6 response between He, Ob
and DM myocytes, suggest that both obesity and type 2 diabetes
results in modifications in satellite cell gene regulation, and that
these alterations are stable enough to persist through multiple cell
divisions and during differentiation into mature myocytes. Indeed,
previous studies have reported donor specific responses to insulin
stimulation [24–27] and we previously demonstrated that an
inflammatory phenotype was conserved in isolated human
myocytes [27]. As the regulation of IL-6 might be substrate
dependent, it is possible that the difference in IL-6 response
observed in the present study could reflect an acceleration of
epigenetic modifications in obesity and type 2 diabetes. Nutritional
environment has been shown to over time induce epigenetic
modifications [33], causing stable alterations in genome structure.
Obesity is a major risk factor for developing type 2 diabetes and
the majority of people with type 2 diabetes are obese. It is tempting
to regard obese people as an intermediate group and obesity as
Table 1. Subject characteristics for muscle biopsy protein analysis, human study 2.
Subjects NGT non-obese NGT obese DM non-obese DM obese
N 1 01 01 09
Gender 5 Male, 5 Female 5 Male, 5 Female 5 Male, 5 Female 5 Male, 4 Female
Age 56.2 (69.5) 52.3 (69.9) 61.7 (612.9) 56.11 (64.0)
BMI 25.3 (62.1) 39.5 (65.6)*** 25.6 (62.5) 37.5 (65.9)***
0 h Glucose (mmol/l) 5.3 (60.5) 5.2 (60.3) 9.9 (63.8) *
$ 12.2 (65.7)***
$$$
2 h Glucose (mmol/l) 6.0 (61.6) 6.4 (60.8) 19.4 (67.8) ***
$$$ 19.4 (66.4)***
$$$
Bonferroni post-tests provided P values for normal glucose tolerant people with obesity (NGT obese) or type 2 diabetes (DM non-obese and DM obese) relative to
normal glucose tolerant control subjects (NGT non-obese);
*P,0.05;
**P,0.01;
***P,0.001. Values are mean 6 SD. Bonferroni post-tests was also performed for DM obese relative to NGT obese and provided P values;
$P,0.05;
$$P,0.01;
$$$P,0.001. Values are mean 6 SD.
doi:10.1371/journal.pone.0039657.t001
Table 2. Subject characteristics for primary muscle cell
cultures, human study 1.
Subjects Healthy Obese Type 2 diabetes
N 777
Gender 4 Male, 3 Female 4 Male, 3 Female 5 Male, 2 Female
Age 56 (67.2) 51 (65.7) 57 (68.6)
BMI 26.1 (62.0) 35.1 (65.8)** 33.4 (63.1)**
0 h Glucose
(mmol/l)
5.7 (60.6) 6.1 (60.6) 8.7 (62.4)**
$$
2 h Glucose
(mmol/l)
6.3 (61.4) 8.2 (60.7) 15.2 (64.3)***
$$$
Bonferroni post-tests provided P values for people with obesity or type 2
diabetes relative to healthy control subjects;
*P,0.05;
**P,0.01;
***P,0.001. Values are mean 6 SD. Bonferroni post-tests provided P values for
people with type 2 diabetes relative to obese subjects;
$P,0.05;
$$P,0.01
$$$P,0.001. Values are mean 6 SD.
doi:10.1371/journal.pone.0039657.t002
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diabetes, making it difficult to interpret a comparison with obese
people that have developed diabetes. Nevertheless, we included
muscle precursor cells from obese people in some of our
experiments and observed a reduced protein expression of IL-
6Ra, as well as a reduced protein expression of IL-6Ra in response
to IL-6, while the STAT3/SOCS3 response seemed to be normal
(although baseline SOCS3 levels tended to be increased). With our
current data, it is not possible to conclude whether the
dysregulation of IL-6 signaling in obesity and type 2 diabetes is
linked or whether it represent two independent phenomena.
Interestingly, IL-6Ra was down regulated in DM tissue but not in
DM myocytes, while being down-regulated in Ob tissue as well as
in Ob myocytes. This could indicate that the underlying
mechanisms for down regulation of IL-6Ra in vivo differ between
obesity and type 2 diabetes. We speculate that Ob myocytes have
developed an increased negative control system of IL-6 signaling
as a protection against the elevated levels of circulating IL-6
occurring in obesity [6]. We argue that this idea is supported by
our finding that IL-6Ra is firmly down regulated at protein level in
He myocytes as a response to prolonged (120 min) IL-6
administration. In contrast, DM myocytes rather seem to have
lost control over IL-6 signaling, signified by an absent down-
regulation of IL-6Ra, increased pSTAT3/STAT3 activation and
a lack of up-regulation of SOCS3 in response to IL-6. Yet, end-
point signaling such as IL-6 mRNA induction and AMPKa2
activation was deficient in another set of DM myocytes.
Interestingly, we have previously demonstrated that pharmaco-
Figure 2. pSTAT3/STAT3 and SOCS3 protein expression in He, Ob and DM myocytes in response to IL-6. (A) Protein expression of
STAT3, pSTAT3 and SOCS3 was assessed in satellite cells isolated from healthy (He) (n=7), obese (Ob) (n=7) and obese people with type 2 diabetes
(DM) (n=7) (Table 2). Satellite cells were differentiated into myocytes and treated with IL-6 (100 ng/ml) or control (PBS) for 30, 60 and 120 min (same
protein samples as in Figure 1 B-D). (B) IL-6 induced phosphorylated STAT3 was related to total STAT3 levels and IL-6 treated samples were presented
as fold change from PBS treated samples. IL-6 induction of pSTAT3 was compared between groups by two-way ANOVAs. (C) Baseline SOCS3 protein
expression in the samples described in A was normalized to total protein expression (as determined by reactive brown staining) and compared
between groups by two-way ANOVAs. (D) IL-6 induced SOCS3 protein expression was normalized to total protein expression and compared between
groups by two-way ANOVAs. Data are presented as fold change (FC) between the control samples presented in A and C and samples treated with IL-6
(100 ng/ml). Data are mean 6 SE. Groups were compared in pairs (i.e. He vs Ob, He vs DM and Ob vs DM) by two-way ANOVAs. Results from ANOVAs
are marked in the figures with connecting capped arcs. *Results from Bonferroni post-tests, relative to He myocytes; *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0039657.g002
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A769662 (100 mM) did not differ between any of the groups
[27]. Whether this discrepancy in response is related to dose (we
used 100 nM of IL-6), exposure time (A769662 was incubated
with cells for 4 hours) or simply activation through separate
pathways, remains elusive.
It is possible that the sensitized STAT3 phosphorylation
accompanied by reduced SOCS3 activation in DM myocytes is
a dysregulation compensating for other diabetes related alterations
in cell signaling in skeletal muscle. For example, we recently
demonstrated that several miRNAs, including two of the myomiRs
(muscle specific miRNAs that regulate muscle cell differentiation)
are differentially expressed in skeletal muscle of people with type 2
diabetes compared to healthy controls [34]. As SOCS3 suppres-
sion of STAT3 activity is an important mechanism during muscle
differentiation [32], we assessed in the current study whether there
was a difference in differentiation capacity of the different cell
groups. Whereas we did not observe any difference in myosin-2
protein expression at the time point when myotubes were formed
and we performed our experiments, it is possible that other
markers, at other stages of differentiation are altered.
A dysfunctional SOCS3 regulation in myocytes of people with
type 2 diabetes is of interest from a broader perspective, as
members of the SOCS protein family not only regulate cytokine
signaling but also has been shown to inhibit insulin receptor signal
transduction [15,35,36]. The SOCS3 connection between IL-6
and insulin signaling could be an explanation to the observation
that mice, when infused with high doses of IL-6 (0.5 mg/h),
induced insulin resistance in skeletal muscle [37]. In support of this
idea, another study demonstrated that lower doses of IL-6 (16 ng/
h), corresponding to levels occurring in diabetic humans, limits the
Table 3. Subject characteristics for primary muscle cell
cultures, human study 2.
Subjects Healthy Type 2 diabetes
N55
Gender Male Male
Age 65.2 (65.4) 60.6 (612.6)
BMI 24.3 (63.8) 32.4 (62.7)**
0 h Glucose (mmol/l) 5.1 (60.6) 9.2 (62.7)**
2 h Glucose (mmol/l) 5.3 (61.7) 12.8 (64.7)*
T-tests provided P values for people with type 2 diabetes were relative to
healthy control subjects;
*P,0.05;
**P,0.01;
***P,0.001. Values are mean 6 SD.
doi:10.1371/journal.pone.0039657.t003
Figure 3. IL-6 induction of IL-6 mRNA in human myocytes. Muscle precursor cells derived from the vastus lateralis muscle of healthy (He), and
obese people with type 2 diabetes (DM) (Table 3) (A) He myocytes (n=5) and DM myocytes (n=5) were treated with recombinant IL-6 or PBS for 60
minutes and IL-6 mRNA expression was assessed using qPCR. (B) Muscle precursor cells derived from healthy (n=4), and obese people with type 2
diabetes (n=4) were differentiated into myocytes and, during the last two days of differentiation transfected with siRNA targeting IL-6Ra. IL-6Ra
knockdown was assessed using qPCR following 48 hrs of transfection. (C) IL-6 mRNA expression following IL-6Ra knockdown was assessed using
qPCR following 48 hrs of transfection. Data were normalized to control treated samples within each cell subject and differences between groups
were assessed using paired t-tests of dCT values. Data are mean 6 SE *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0039657.g003
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higher expression of SOCS3 than muscle, while muscle remained
unaffected [38]. We were not able to detect any significant
differences in basal SOCS3 protein expression in the cell groups.
However, Rieusset et al. previously demonstrated that SOCS3
mRNA levels were up regulated in skeletal muscle of people with
type 2 diabetes but not in muscle of people with obesity only,
despite comparable elevated plasma levels of IL-6 [39]. Taken
together, regulation of the IL-6/STAT3/SOCS3 pathway in
muscle cells seems to change with obesity, possibly due to
alterations in circulating cytokine levels and composition. It
remains elusive whether the additional changes to this pathway
contributes to the manifestation of type 2 diabetes or represent
secondary effects of the disease.
Acute stimulation with IL-6 has been shown to increase fatty
acid turnover in vivo [40] and AMPKa2 activity [19,20], fat
oxidation [40–42] and glucose uptake [22,40,41,43] in vitro in
skeletal muscle cells. Thus, a deficient IL-6 signaling might have
severe consequences for the regulation of metabolic rate in skeletal
muscle. In the present study we demonstrated that IL-6 potently
induces AMPKa2 activity in He myocytes, but not in DM
myocytes derived from individuals with diabetes. Several studies
have demonstrated that IL-6 stimulates fatty acid metabolism in
rodent skeletal muscle by the activation of AMPK [19–21]. Thus,
an IL-6 resistant muscle may suffer from a compromised energy
regulation, independently of the insulin pathway. A similar
deficiency has been reported for leptin signaling in myocytes
derived from obese subjects in comparison to lean [44]. Here,
myocytes from obese subjects failed to activate AMPK in response
to leptin administration, accompanied by a corresponding de-
ficiency in palmitate oxidation [44]. However, while IL-6 activated
AMPKa2 8-fold in He myocytes in our study but had no effect on
AMPKa1, leptin increased both AMPKa1 and AMPKa2
(approximately 2-fold) [44], suggesting that IL-6 is a more potent
and specific stimulant of AMPKa2. It is therefore tempting to
suggest that a deficiency in IL-6 signaling might have even more
severe consequences for AMPKa2 downstream signaling than
a deficiency in leptin signaling, possibly limiting both fatty acid
oxidation and glucose uptake in the diabetic muscle. Indeed, IL-6
knockout mice develop moderate obesity, glucose intolerance and
dyslipidemia at 9 months of age [45].
The role of IL-6 in muscle metabolism is further elucidated by
the recent report that IL-6 stimulate insulin secretion via GLP-1
induction [11], suggesting that the increased levels of IL-6
associated with obesity and insulin resistance might be a compen-
satory mechanism (i.e. an increased IL-6 production is initiated to
induce more insulin). However, this chronic exposure of elevated
IL-6 levels might have severe effects on IL-6 signaling in skeletal
muscle. A chronic IL-6 stimulation may interfere with the
regulation of IL-6 signaling and indeed we here report a down
regulation of the IL-6Ra receptor in skeletal muscle biopsies of
people with obesity and a deficient downstream IL-6 signaling in
DM myocytes.
Our data indicate that negative control of IL-6 signaling is
increased in myocytes in obesity, whereas a dysfunctional IL-6
signaling is established further downstream of IL-6Ra in DM
myocytes, resulting in a failure in activating gene expression and
metabolic rate. Our data raises the idea that additional growth
signaling pathways might be altered in skeletal muscle of people
with type 2 diabetes. Further studies of these pathways in isolated
myocytes might provide a substantial contribution to the current
view of the muscular pathophysiology of type 2 diabetes mellitus.
Materials and Methods
Ethics Statement
Permission to undertake the human studies, from which muscle
tissue and satellite cells were obtained, was approved by the Ethics
Committee of Copenhagen and Frederiksberg Communities,
Denmark (KF 01-141/04) (human study 1) and (H-C-2008-101)
(human study 2). The participants were given oral and written
information about the experimental procedures. All volunteers
gave their written consent before participation. Both studies were
carried out in accordance with the principles of the Declaration of
Helsinki as revised in 2000.
Figure 4. AMPK activity in response to IL-6 in myocytes from healthy and people with type 2 diabetes. Muscle precursor cells derived
from the vastus lateralis muscle of healthy (He) (n=5), and obese people with type 2 diabetes (DM) (n=5) (Table 3), were differentiated into myocytes
and were treated with recombinant IL-6 for 30 or 60 minutes. Controls (Ctrl) were treated with PBS for 60 minutes. Protein was isolated and AMPK
activity was measured (A) AMPK a1 activity in response to IL-6 was compared between groups by a two-way ANOVA. (B) AMPK a2 activity in response
to IL-6 was compared between groups by a two-way ANOVA. While there was no effect of group, there was an interaction (P,0.01) and thus
Bonferroni post-tests were performed. Effect of treatment within groups was performed by one-way ANOVAs. Data are mean 6 SE. *Results from
Bonferroni post-tests, relative to He myocytes; *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0039657.g004
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We utilized material from two previously described studies.
Human study 1, was described previously [27] and was approved
by the regional research ethics committee (H-C-2008-101). From
this study, satellite cells were isolated from non-obese persons, and
from obese persons with and without type 2 diabetes (n=7 in each
group, Table 2). From human study 2 (H-KF-01-141/04),
additional satellite cell cultures were obtained. Subjects and study
protocol have been described previously [6,46–48]. One sub-set
(non-obese persons or individuals that had type 2 diabetes n=5 in
each group, Table 3) was utilized for satellite cell isolations.
Another subset of the samples (non-obese, obese persons or
individuals that had type 2 diabetes n=9–10 in each group, Table
I) was utilized for protein analysis. The participants in both studies
were divided into distinct groups according to BMI (#30 or
.30 kg/m
2), categorized as non-obese or obese and, according to
the WHO definition, normal glucose tolerant, impaired glucose
tolerant and the diagnosis of type 2 diabetes.
Satellite Cell Culture
Satellite cells were isolated from muscle biopsies as previously
described [33]. Unless otherwise stated, all cell culture reagents
were from Invitrogen, Carlsbad, CA, USA. Briefly, a muscle
biopsy was obtained from vastus lateralis and minced and digested
in 5 ml HamF10 media containing 50% trypsin EDTA (16) and
5 mg collagenase IV (Sigma-Aldrich, St.Louis, MO, USA) and
BSA (Sigma-Aldrich) in 37uC for 5 minutes. The digestion solution
was inactivated in serum on ice and the procedure was repeated.
The digestion solution was filtered and centrifuged at 800 g for 7
minutes. Following washing with HamF10, cells were pre-plated in
a 60 mm culture plate, to diminish fibroblast contamination. After
3 hours incubation, the cell suspension was transferred to a 25 cm
3
flask coated with matrigel (BD, Franklin Lakes, NJ, USA). The
media, HamF10, 20% FBS, 1% Penicillin/Streptomycin and 1%
Fungizone, was changed on day 4 after isolation and thereafter
every second day. Cell cultures were expanded from the 25 cm
3
flask to a 10 cm plate, which were assigned passage (P) 1.
Thereafter, cells were split 1:3 at 75% confluence. Experiments
were performed on cells at P3–P4. For differentiation, cells were
seeded in DMEM low glucose, 10% FBS, 1% Penicillin/
Streptomycin and, upon confluence, media was changed to
DMEM high glucose, 2% horse serum, 1% Penicillin/Streptomy-
cin. At day 5 in low serum, the majority of the cells had fused into
myotubes with polynucleated status. Cells were treated with
human recombinant IL-6 (R&D systems, Minneapolis, MN, USA)
for 30, 60 or 120 minutes at a concentration of 100 ng/ml, if not
indicated otherwise in the figure legends and harvested in cell lysis
buffer for AMPK activity or Western Blot analysis or Trizol for
RNA and subsequent gene expression analysis.
siRNA Transfection of Myocytes
Transfections on human myoblasts and myotubes were
performed using siRNA pools consisting of four siRNA oligos
specifically targeting four different sites of target mRNA (IL6Ra)
(On Target Plus) (Dharmacon). The purpose of the siRNA pools is
to use less of each oligo to minimize any off-target effects.
Transfections were performed using lipofectamine 2000 (Invitro-
gen, Taastrup, Denmark), according to the manufacturer’s
protocol, with 100 nM of siRNA, at day 3 of differentiation in
antibiotic-free cell culture media (see above), for 48 h. A
scrambled non-specific oligonucleotide (siRNA Scr) was used as
control.
Immunofluorescence
Myoblasts were differentiated in chamber slides pre-coated with
poly-L-lysin and matrigel. At day 5 of differentiation, myocytes
were permeablized and fixed with methanol at 220uC for 6
minutes. Non-specific binding sites were blocked in PBS contain-
ing 2% BSA over night at +8uC. Primary antibody targeting
MYH2 (MF20, DSHB) was diluted 1:50 in PBS containing 5%
goat serum while secondary antibody (Alexa-fluor 488, Molecular
Probes/Invitrogen) was diluted 1:1000 in PBS. Primary and
secondary antibody incubations were performed at 37uC for 60
and 30 min, respectively. Nuclei were stained with DAPI for 10
minutes at room temperature. Between all steps, cells were washed
for 365 min with PBS at RT. Stained myocytes were mounted
using Vectashield Mounting Medium and sealed with nailpolish.
Myocytes were examined and photographed under a Zeiss LSM
710 on Axio Imager at 406 magnification. The same size of
photograph was obtained from each slide and all DAPI positive
cells in the photograph were counted. To estimate a fusion index,
the number of DAPI positive cells within MYH2 positive
myotubes was divided with the total number of DAPI positive
cells.
Western Blotting
Human muscle samples were homogenized using a Tissuelyser
(Qiagen, Valencia CA, USA) in 50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 0.25% NaDeox-
ycholate, 1% Triton X-100. Cell samples were harvested in lysis
buffer (Cell signaling technology, Danvers, MA, USA)). Phospha-
tase inhibitor cocktail 1 and 2 (SigmaAldrich) and protease
inhibitor complete mini (Roche) was added fresh to the buffer.
Protein concentration was measured using a colorimetric protein
assay (Bio-Rad) and samples were diluted in 5 6Laemmli buffer
and boiled for 2 min before loading of 25 mg of muscle tissue
lysates or 10 mg of cell lysates onto a 4%–12% gradient bis-Tris
NuPage gel (Invitrogen). Protein was transferred onto a PVDF
membrane using a semi-dry blotting system for 1 h and 30
minutes at 20 V (Invitrogen). The membrane was blocked for 1 h
in 5% milk and incubated with primary antibody overnight at
4uC. Antibodies were against: IL-6Ra (Santa Cruz), STAT3, p-
STAT3(tyr
705), SOCS3 (all from Cell Signaling Technology). Blots
were washed and incubated with secondary IgG HRP conjugated
antibody (Cell Signaling Technology). Signal was detected using
Supersignal West Femto Luminal/Enhancer Solution (Thermo
Scientific) and subsequent exposure in a charge-coupled device
camera (Bio-Rad). Blots were incubated in 0.5% Reactive Brown
(Sigma Aldrich) for 15 min. Blots were analyzed and quantified
using ImageQuant software, using reactive brown as a measure of
total protein and for normalization for loading and transfer.
AMPK Activity Assay
Protein lysates were performed and quantified as described
above. AMPK activity was assessed as previously described [34].
Briefly, 100 mg of protein was immunoprecipitated with antibody
specific to the a2o ra1 catalytic subunit of AMPK (Bethyl
antibodies) and protein A/G Sepharose beads over night at 4u.
Beads were washed five times, and the activity of the immobilized
enzyme was assayed based on the phosphorylation of ‘‘SAMS’’
peptide (0.2 mmol/l) by 0.2 mmol/l ATP (containing 2 mCi [c-
32P] ATP) in the presence and absence of 0.2 mmol/l AMP.
Label incorporation into the SAMS peptide was measured on
a Beckman LS6500 scintillation counter.
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Skeletal muscle biopsy samples were homogenized in TRIzol
(Invitrogen) using a Tissuelyser (Qiagen) and total RNA was
isolated according to the manufacturer’s protocol. Total RNA was
dissolved in nuclease-free water and quantified using a Nanodrop
ND 1000 (Saveen biotech ApS, A ˚rhus, Denmark). Total RNA
(0.5 mg) was reverse-transcribed using cDNA high capacity kit
(Applied Biosystems) according to the manufacturer’s protocol.
CDNA samples were loaded in triplicates and quantitative real-
time PCR (qPCR) was performed using an ABI-PRISM 7900
Sequence Detection system (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s protocol. IL-6 Primers and
MGB probe were designed using Primer Express software (Applied
Biosystems) (IL-6 forward primer: 59-ctgcagaaaaaggcaaagaatctag,
IL-6 reverse primer: 59-tctgtgcctgcagcttcgt, IL-6 MGB probe: 59-
cacccctgacccaac). IL-6Ra primers were designed using Roche
Universal probe library (Roche), IL-6Ra forward primer:
59agtaccactgcccacattcc, IL-6Ra reverse primer: 59-cagcttc-
cacgtcttcttga. A pre-optimized assay for 18 S rRNA was used as
endogenous control (Applied Biosystems). To assess amplification
efficiency, two fold dilutions series were performed for IL-6, IL-
6Ra and 18 S. Based on these, cDNA was diluted 1:10 for IL-6
and IL-6Ra and 1:200 for 18 S, to ensure linear amplification.
RefSeq Accession numbers are: IL-6: NM_000600.3, IL-6Ra:
NM_000565.2.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
software. All data are presented as mean 6 SE. Two-way Anova
(Repeated measures) was used for comparisons of time and
metabolic group. Comparisons of pairs were performed (He vs
Ob, He vs DM and Ob vs DM). When relevant and as specified in
figure legends, Bonferroni post-hoc tests were performed. QPCR
data were presented normalized to control treated samples within
each cell subject and differences between groups were assessed
using t-tests of dCT values. When relevant and as specified in
figure legends and/or results, one-way Anova was utilized to assess
regulation over time within each cell group. Sample size and
significance level for each analysis are as stated in figure legends. A
P-value of 0.05 was considered significant.
Supporting Information
Figure S1 IL-6Ra protein expression in human muscle
tissue. All blots for the data presented in Figure 1A are shown.
Samples are from non-obese, normal glucose tolerant subjects
(NGT), obese normal glucose tolerant subjects (Ob), non-obese
subjects with type 2 diabetes (DM) and obese subjects with type 2
diabetes (DMO).
(TIFF)
Figure S2 IL-6Ra knockdown in He vs DM myocytes. (A)
Comparison between dCT values in samples treated with IL-6Ra
for the two groups. (B) Comparison between IL-6Ra knockdown
and IL-6 mRNA expression. Linear regression analyses were
performed on the data presented in Figure 3B and 3C.
(TIFF)
Figure S3 Differentiation status of myocytes derived
from healthy, obese or people with type 2 diabetes.
Muscle precursor cells derived from the vastus lateralis muscle of
healthy, obese and obese people with type 2 diabetes (Table 2)
were differentiated into myocytes on chamber slides. (A) Myocytes
were immunostained for Myosin-2 and counterstained with DAPI.
(B) The amount of DAPI positive cells within Myosin-2 positive
myotubes was divided with the total number of DAPI positive
cells, to estimate a fusion index. Data are mean 6 SE (n=5–6 in
each group).
(TIFF)
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